Kinase Inhibitors in the Treatment of Myeloid Malignancies
Ann Mullally, MD, Editor Aberrant signaling pathway activation is a central feature of myeloid malignancies. With the development of the tyrosine kinase inhibitor, imatinib, to treat chronic myelogenous leukemia (CML),…
